James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
Thanks! Share it with your friends!
James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
![Chronic Pain Attack [Oh my God, babe??] [Public Place] [Let's Get You Home]](https://i.ytimg.com/vi/3UPe96zlzpk/hqdefault_live.jpg "Chronic Pain Attack [Oh my God, babe??] [Public Place] [Let's Get You Home]")
){kind=link}
Comments